Independent directory Public ClinicalTrials.gov records United States
Clear filters
ClinicalTrials.gov public records Last synced Sep 12, 2026, 5:07 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Showing 1–13 of 13 matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
Conditions
Colorectal Neoplasms
Interventions
Bevacizumab, Capecitabine, Levocetirizine
Drug
Lead sponsor
Washington University School of Medicine
Other
Eligibility
18 Years and older
Enrollment
47 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2013 – 2015
U.S. locations
1
States / cities
St Louis, Missouri
Conditions
Seasonal Allergic Rhinitis
Interventions
levocetirizine dihydrochloride, placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
580 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
38
States / cities
Tucson, Arizona • Los Angeles, California • Sacramento, California + 35 more
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine 1.25 mg, Placebo
Drug · Other
Lead sponsor
UCB Pharma
Industry
Eligibility
6 Months to 11 Months
Enrollment
69 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Birmingham, Alabama • Hot Springs, Arkansas • Jonesboro, Arkansas + 23 more
Completed Phase 2Phase 3 Interventional Results available

Characterization of the Role of Histamine in Children With Asthma

NCT01392859
Conditions
Asthma, Allergic Asthma, Non-allergic Asthma
Interventions
Levocetirizine 0.5 Mg/mL Oral Solution
Drug
Lead sponsor
Children's Mercy Hospital Kansas City
Other
Eligibility
7 Years to 17 Years
Enrollment
211 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2011 – 2015
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Rhinitis, Urticaria
Interventions
levocetirizine or placebo
Drug
Lead sponsor
Wake Forest University
Other
Eligibility
18 Years to 60 Years
Enrollment
11 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Winston-Salem, North Carolina
Conditions
Perennial Allergic Rhinitis
Interventions
levocetirizine (Xyzal), placebo
Drug
Lead sponsor
AAADRS Clinical Research Center
Other
Eligibility
12 Years to 65 Years
Enrollment
30 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2009
U.S. locations
1
States / cities
Coral Gables, Florida
Completed Phase 4 Interventional Results available

Is Levocetirizine Less Sedating Than Cetirizine?

NCT00826943
Conditions
Allergic Rhinitis
Interventions
Cetirizine, Levocetirizine, Placebo
Drug
Lead sponsor
Vanderbilt University
Other
Eligibility
18 Years to 77 Years
Enrollment
30 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009
U.S. locations
1
States / cities
Nashville, Tennessee
Completed Phase 4 Interventional Results available

Management of Pruritus With Xyzal in Atopic Dermatitis

NCT00884325
Conditions
Atopic Dermatitis, Pruritus
Interventions
Levocetirizine dihydrochloride (Xyzal), placebo
Drug
Lead sponsor
Derm Research, PLLC
Other
Eligibility
18 Years and older
Enrollment
40 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2009 – 2010
U.S. locations
1
States / cities
Louisville, Kentucky
Conditions
Allergic Asthma
Interventions
Levocetirizine Dihydrochloride, Placebo
Drug
Lead sponsor
Bridgette Jones
Other
Eligibility
6 Years to 17 Years
Enrollment
55 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2021 – 2026
U.S. locations
1
States / cities
Kansas City, Missouri
Conditions
Rhinitis Allergic, Persistent
Interventions
Not listed
Lead sponsor
UCB Pharma
Industry
Eligibility
2 Years and older
Enrollment
7,870 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2007 – 2008
U.S. locations
1
States / cities
Smyrna, Georgia
Completed Phase 1 Interventional Accepts healthy volunteers

A Phase I Study of LY3471851 in Healthy Participants

NCT05565729
Conditions
Healthy
Interventions
LY3471851, Placebo, Levocetirizine
Drug
Lead sponsor
Nektar Therapeutics
Industry
Eligibility
18 Years to 64 Years
Enrollment
41 participants
Healthy volunteers
Accepts healthy volunteers
Timeline
2022 – 2023
U.S. locations
1
States / cities
Dallas, Texas
Conditions
Allergic Rhinitis, Chronic Urticaria
Interventions
Levocetirizine, Placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
2 Years to 6 Years
Enrollment
173 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
28
States / cities
Birmingham, Alabama • Little Rock, Arkansas • Beverly Hills, California + 25 more
Conditions
Seasonal Allergic Rhinitis
Interventions
levocetirizine dihydrochloride, placebo
Drug
Lead sponsor
UCB Pharma
Industry
Eligibility
18 Years to 65 Years
Enrollment
596 participants
Healthy volunteers
Healthy volunteers not accepted
Timeline
2008
U.S. locations
26
States / cities
Scottsdale, Arizona • Hot Springs, Arkansas • Little Rock, Arkansas + 23 more